Capital Fund Management (CFM)
BEAM icon

Capital Fund Management (CFM)’s Beam Therapeutics BEAM Stock Holding History

Capital Fund Management (CFM)’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,700
Closed -$486K – 1880
2024
Q1 		$486K Buy
+14,700
New +$458K ﹤0.01% 1865

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Capital Fund Management (CFM)'s BEAM Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Beam Therapeutics (BEAM) in Q3 2025, closing a stake of 38,438 shares — an estimated $654K sold.

Capital Fund Management (CFM) first reported a position in BEAM in Q1 2022 and held it in 10 quarters. The position peaked at $2.66M in Q4 2022. 219 funds tracked by Wall St. Rank hold BEAM as of Q3 2025.

  • Capital Fund Management (CFM) reported no remaining Beam Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 38,438 Beam Therapeutics shares in Q3 2025, an estimated $654K.
  • Capital Fund Management (CFM) first reported a position in Beam Therapeutics in Q1 2022 and held it in 10 quarters.
  • Capital Fund Management (CFM)'s Beam Therapeutics position peaked at $2.66M in Q4 2022.
  • 219 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.